Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:CRSP News 19 October 2025 - 24 January 2026

CRISPR Therapeutics stock drops 9% after CEO sale filing — what CRSP investors watch next week

CRISPR Therapeutics stock drops 9% after CEO sale filing — what CRSP investors watch next week

CRISPR Therapeutics shares fell 8.7% to $55.52 Friday, with 2.4 million shares traded. CEO Samarth Kulkarni sold 90,000 shares under a prearranged plan, SEC filings show. Bank of America lowered its price target to $89, citing trimmed 2026 Casgevy forecasts. Other gene-editing stocks also dropped sharply as sector volatility increased.
24 January 2026
····
CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics shares slipped 0.5% to $60.51 in premarket trading Friday after CEO Samarth Kulkarni sold 90,000 shares for about $5.2 million under a preset plan, an SEC filing showed. The stock had surged 11.1% Thursday on heavy volume. Options trading spiked, with focus on April $90 calls. Bank of America trimmed its price target to $89 but kept a Buy rating.
23 January 2026
····
CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next

CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next

New York, Jan 11, 2026, 17:56 EST — The market has closed for the day. CRISPR Therapeutics AG slipped 4.5% to $53.84 on Friday, putting the gene-editing stock under pressure as biotech leaders and investors gear up to converge in San Francisco this week. (CrisprTx) U.S. markets remain closed Sunday, yet the J.P. Morgan Healthcare Conference frequently shapes the tone for the opening quarter, bringing deal rumors, pipeline updates, and occasional unexpected guidance shifts. This year, major drug patent expirations are forcing big pharma to chase fresh assets, with the biotech ETF XBI hitting a four-year peak, the Financial Times
12 January 2026
···
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

New York, Jan 9, 2026, 15:11 EST — Regular session CRISPR Therapeutics AG shares slid on Friday, bucking a firmer broader market, after a regulatory filing flagged a chief financial officer’s share sale under a pre-arranged trading plan. (Reuters) The company’s CFO, Raju Prasad, exercised stock options for 29,700 common shares and sold 29,700 shares the same day at prices around $60, a Form 4 filed on Jan. 8 showed. The filing indicated the sales were made under a Rule 10b5-1 plan, a preset trading instruction meant to limit allegations of trading on inside information. (SEC) The timing matters because
9 January 2026
········
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

NEW YORK, January 1, 2026, 18:59 ET — Market closed Shares of CRISPR Therapeutics AG ended the last trading session of 2025 down 1.4% at $52.44. U.S. stock markets were closed on Thursday for New Year’s Day, according to the NYSE holiday calendar. StockAnalysis+1 The pullback matters because CRISPR heads into 2026 with its first commercial product still early in launch and with investors seeking clearer signs of demand. The stock has tended to react sharply to shifts in sentiment around gene-editing drugmakers. Traders are also looking ahead to the next set of checkpoints: read-throughs from partner Vertex Pharmaceuticals, which
2 January 2026
········
CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

NEW YORK, Dec. 27, 2025, 4:58 p.m. ET — Market closed (U.S. equities are shut for the weekend) CRISPR Therapeutics AG (NASDAQ: CRSP) heads into the final trading stretch of 2025 with investors balancing two forces that often define biotech stocks: headline-driven momentum and long-duration fundamental risk. The stock finished the most recent regular session (Friday, Dec. 26) at $55.08, down 2.87%, after trading between $56.54 and $53.76. In after-hours trading, CRSP was last shown around $55.24 late Friday evening. StockAnalysis That Friday move came against a holiday-thinned tape on Wall Street. Reuters described the broader market session as light-volume
27 December 2025
···
CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

Updated: December 4, 2025 Key takeaways CRISPR Therapeutics stock today: price, volatility and positioning As of pre‑market trading on December 4, 2025, CRISPR Therapeutics AG (NASDAQ: CRSP) is changing hands at roughly $56, just above Wednesday’s close of $55.99, after jumping 8.5% in the last regular session. stockinvest.us+1 Over the past 12 months, CRSP has traded between about $30.04 and $78.48, leaving today’s price squarely in the middle of its 52‑week range. stockinvest.us A few quick stats: Technically, services like StockInvest.us classify CRSP as a “hold/accumulate” with a wide expected three‑month range (~$43–$64), while Intellectia’s model calls it a “Strong
4 December 2025
·····
Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Current News Stock Price and Market Activity CRSP is trading around the mid-$60s ahead of Monday’s open. By Reuters (Nov 2) it was ~$64.04 (up +4.86% on the day) Reuters. (Nasdaq closes on Oct 31 showed ~$63.99 Reuters.) Over the past month CRSP has gained roughly 17% Genengnews, boosted by recent data releases. For example, a 3-day rally in mid-Oct lifted CRSP ~5% after the SyNTase/CTX460 results were announced Genengnews. Technical indicators are mixed: the 14-day RSI is ~50 (neutral) and the MACD is slightly negative Investing. Shorter moving averages (5/10/20-day around $63–$63.8) are giving buy signals Investing, but the
2 November 2025
·······
CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Clinical and Pipeline Progress CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1 antitrypsin deficiency (AATD). The data – highlighted at the ESGCT conference – showed that a single dose of CTX460 delivered by lipid nanoparticles corrected the disease-causing mutation in >90% of liver cells and boosted functional AAT protein ~5-fold in animal models globenewswire.com. “The preclinical results demonstrate the potential of CTX460, developed using our novel SyNTase editing platform, to correct the mutation with precision and efficiency,” said CRISPR CMO
19 October 2025
····

Stock Market Today

Nvidia stock jumps nearly 8% as Big Tech AI spending bets lift chipmakers and Dow tops 50,000

Nvidia stock jumps nearly 8% as Big Tech AI spending bets lift chipmakers and Dow tops 50,000

7 February 2026
Nvidia surged 7.8% Friday, leading a chip stock rally that pushed the Dow above 50,000 for the first time. The PHLX semiconductor index gained 5.7% as Advanced Micro Devices rose 8.3% and Broadcom 7.1%. Amazon fell 5.6% after projecting $200 billion in 2026 capital spending. Investors weighed a $600 billion AI infrastructure outlay against sharp losses in software shares.
Glencore share price steadies after Rio Tinto walks away — what to watch next week

Glencore share price steadies after Rio Tinto walks away — what to watch next week

7 February 2026
Glencore shares closed up 0.6% at 478.1 pence Friday, rebounding after a 7% drop following the collapse of merger talks with Rio Tinto. The company is expected to announce the sale of its Kazzinc stake soon and has signed a non-binding agreement with Orion for a potential $9 billion deal in the DRC. Investors await Glencore’s full-year results on Feb. 18 for further guidance.
Go toTop